Sunzen Biotech Berhad Dirección

Dirección controles de criterios 3/4

El CEO de Sunzen Biotech Berhad es Yek Teo , nombrado en Jun 2020, tiene una permanencia de 4.42 años. compensación anual total es MYR320.94K, compuesta por 84.1% salario y 15.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 15.19% de las acciones de la empresa, por valor de MYR37.33M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 4.3 años, respectivamente.

Información clave

Yek Teo

Chief Executive Officer (CEO)

RM 320.9k

Compensación total

Porcentaje del salario del CEO	84.1%
Permanencia del CEO	4.4yrs
Participación del CEO	15.2%
Permanencia media de la dirección	3yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations

Nov 07

Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit

Oct 15

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Aug 06

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

May 25

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

May 24

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Apr 22

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Nov 16

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Mar 26

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Dec 10

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Yek Teo en comparación con los beneficios de Sunzen Biotech Berhad?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	RM 321k	RM 270k	RM 6m
Dec 31 2023	n/a	n/a	RM 7m
Sep 30 2023	n/a	n/a	RM 5m
Jun 30 2023	n/a	n/a	RM 4m
Mar 31 2023	n/a	n/a	RM 4m
Dec 31 2022	RM 214k	RM 175k	RM 4m
Sep 30 2022	n/a	n/a	RM 3m
Jun 30 2022	n/a	n/a	RM 2m
Mar 31 2022	n/a	n/a	RM 2m
Dec 31 2021	RM 148k	RM 120k	RM 680k
Sep 30 2021	n/a	n/a	-RM 9m
Jun 30 2021	n/a	n/a	-RM 9m
Mar 31 2021	n/a	n/a	-RM 11m
Dec 31 2020	RM 74k	RM 65k	-RM 13m

Compensación vs. Mercado: La compensación total de Yek($USD71.68K) está por debajo de la media de empresas de tamaño similar en el mercado MY ($USD108.82K).

Compensación vs. Ingresos: La compensación de Yek ha aumentado más de un 20% en el último año.

CEO

Yek Teo (40 yo)

4.4yrs

Permanencia

RM 320,938

Compensación

Mr. Yek Ming Teo serves as Executive Director at Sunzen Biotech Berhad since June 16, 2020 and served as its Group Managing Director cum Group Chief Executive Officer since June 16, 2020 until February 25,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Chee Ching	Executive Chairman	4.3yrs	RM 114.52k	0.53% MYR 1.3m
Yek Teo	Group MD & Executive Director	4.4yrs	RM 320.94k	15.19% MYR 37.3m
Tong Phang	Chief Financial Officer	no data	sin datos	sin datos
Wee Lim	Sales & Marketing Director	no data	sin datos	sin datos
Mee Teo	Company Secretary	10yrs	sin datos	sin datos
Weng Cheng	Joint Company Secretary	less than a year	sin datos	sin datos

3.0yrs

Permanencia media

47.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SUNZEN se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Chee Ching	Executive Chairman	4.3yrs	RM 114.52k	0.53% MYR 1.3m
Yek Teo	Group MD & Executive Director	4.4yrs	RM 320.94k	15.19% MYR 37.3m
Yew Lee	Non Independent Non-Executive Director	4.3yrs	RM 96.80k	sin datos
Kien Khoo	Independent Non-Executive Director	10.3yrs	RM 43.80k	sin datos
Long Poo	Independent & Non-Executive Director	1.7yrs	RM 39.06k	0.011% MYR 26.2k
Aida Binti Abdullah	Senior Independent & Non Executive Director	less than a year	RM 35.40k	sin datos

4.3yrs

Permanencia media

49yo

Promedio de edad

Junta con experiencia: La junta directiva de SUNZEN se considera experimentada (4.3 años de antigüedad promedio).

Sunzen Biotech Berhad Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad Announces Appointment of Aida Lim Binti Abdullah as Independent and Non Executive Member of Nomination Committee

Sunzen Biotech Berhad Announces Resignation of Zeenath Begum Binti Mohamed Mastan as Joint Company Secretary

Sunzen Biotech Berhad Announces Appointment of Lee Yew Weng as Non Independent and Non Executive Member of Remuneration Committee

Sunzen Biotech Berhad Appoints Lee Yew Weng as Non Independent and Non Executive Member of Nomination Committee

Recent updates

Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit

New major risk - Shareholder dilution

Sunzen Biotech Berhad (KLSE:SUNZEN) acquired additional 30% stake in Ecolite Biotech Manufacturing Sdn Bhd from group of sellers for MYR 15 million.

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Now 22% undervalued

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Sunzen Biotech Berhad Announces Appointment of Aida Lim Binti Abdullah as Independent and Non Executive Member of Nomination Committee

Third quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 3Q 2022)

Sunzen Biotech Berhad Announces Resignation of Zeenath Begum Binti Mohamed Mastan as Joint Company Secretary

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Sunzen Biotech Berhad Announces Appointment of Lee Yew Weng as Non Independent and Non Executive Member of Remuneration Committee

Sunzen Biotech Berhad Appoints Lee Yew Weng as Non Independent and Non Executive Member of Nomination Committee

Second quarter 2023 earnings released: EPS: RM0.001 (vs RM0.001 in 2Q 2022)

Sunzen Biotech Berhad Announces the Resignation of Dr. Fong Chan Seng as Independent and Non Executive Director, Member of Remuneration Committee, Chairman of Nomination Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 1Q 2022)

Sunzen Biotech Berhad Announces Redesignation of Ching Chee Pun as Executive Chairman

Full year 2022 earnings released: EPS: RM0.005 (vs RM0.001 in FY 2021)

Third quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 3Q 2021)

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 2Q 2021)

First quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 1Q 2021)

Sunzen Biotech Berhad Announces Resignation of Lim Lee Kuan as Company Secretary

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sunzen Biotech Berhad Announces the Re-Designation of Teo Yek Ming from Group Chief Executive Officer to Group Managing Director

Sunzen Biotech Berhad (KLSE:SUNZEN) completed the acquisition of Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap.

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Full year 2020 earnings released: RM0.025 loss per share (vs RM0.034 loss in FY 2019)

New 90-day high: RM0.22

Sunzen Biotech Berhad (KLSE:SUNZEN) entered into a conditional share sale agreement to acquire Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap for MYR 12.4 million.

New 90-day high: RM0.20

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Third quarter 2020 earnings released: RM0.001 loss per share

Sunzen Biotech Berhad Announces Re-Designation of Ching Chee Pun from Non-Independent Director to Executive Director

First half earnings released

New 90-day high - RM0.21

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad